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Abstract—An elevated urinary albumin excretion rate (UAER) is associated with an increased risk of cardiovascular
mortality, but the pathophysiological mechanism underlying this association is poorly understood. To investigate the
role of endothelial dysfunction, leukocyte adhesion, and low-grade inflammation (1) in the development of elevated
UAER (study I) and (2) in linking elevated UAER with risk of cardiovascular mortality (study II), we performed a
prospective study in an age–, sex–, and glucose tolerance–stratified sample of a population-based cohort aged 50 to 75
years. High levels of von Willebrand factor, soluble vascular cell adhesion molecule-1 (sVCAM-1), and C-reactive
protein (CRP) were used as markers of endothelial dysfunction, leukocyte adhesion, and low-grade inflammation,
respectively. For study I, subjects who had normal UAER at baseline (n316 subjects, 66 with type 2 diabetes) were
reexamined after a mean follow-up of 6.1 years. The development of elevated UAER was defined as a mean
albumin-to-creatinine ratio 2.0 mg/mmol at follow-up. Age–, sex–, and glucose tolerance–adjusted logistic regression
analyses showed the development of elevated UAER to be significantly associated with levels of sVCAM-1 and CRP
(odds ratio 1.14 [95% CI 1.02 to 1.27] per 10% increase of sVCAM-1 and odds ratio 1.17 [95% CI 1.04 to 1.32] per
50% increase of CRP). The results were not materially different after additional adjustment for hypertension, body mass
index, cardiovascular disease, and creatinine clearance or stratification by the presence of diabetes. For study II, the vital
status of all subjects (n575) was determined after a mean follow-up of 6.6 years. Eighty-one of 575 subjects died (30
died of cardiovascular disease). The presence of elevated UAER at baseline was associated with a 4.1-fold (1.94 to 8.73)
increased risk of cardiovascular death after adjustment for age, sex, and glucose tolerance status. Adjustment for levels
of von Willebrand factor, sVCAM-1, or CRP did not materially affect the results, nor did additional adjustment for the
presence of hypertension, retinopathy, and cardiovascular disease and for levels of homocysteine, triglycerides, and high
density lipoprotein cholesterol. Leukocyte adhesion (sVCAM-1) and low-grade inflammation (CRP) are determinants
of the development of elevated UAER. However, these determinants do not explain the association between elevated
UAER and cardiovascular mortality. (Arterioscler Thromb Vasc Biol. 2002;22:593-598.)
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Elevated urinary albumin excretion rate (UAER) is asso-ciated with an increased risk of cardiovascular disease
among individuals with and without type 2 diabetes.1,2 The
pathophysiological mechanism linking elevated UAER to
cardiovascular disease is unknown; the most commonly held
view is that elevated UAER reflects a pathophysiological
process predisposing an individual to atherothrombosis.3
Atherothrombosis is a low-grade inflammatory disease of the
vessel wall characterized by endothelial dysfunction and an
increased transendothelial passage of leukocytes.4 Therefore,
these features could be the pathogenic factor linking elevated
UAER to cardiovascular disease.
In support of this hypothesis, increased plasma levels of
von Willebrand factor (vWf), a marker of endothelial dys-
function,5 have been associated not only with an increased
risk of cardiovascular events6,7 but also with the development
of elevated UAER.8,9 In addition, increased plasma levels of
soluble vascular cell adhesion molecule-1 (sVCAM-1), an
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adhesion molecule that reflects the recruitment of leukocytes
into the vessel wall,10 have been associated with the risk of
cardiovascular death on one hand and of elevated UAER on
the other.11 Finally, increased levels of C-reactive protein
(CRP), an acute-phase reactant, reflect inflammatory activity
and are associated with an increased risk of cardiovascular
mortality.7,12 Acute inflammation is associated with increased
urinary protein excretion13 and elevated UAER.14 Con-
versely, the presence of elevated UAER is associated with
increased levels of proinflammatory cytokines.15
In view of these considerations, we performed a prospec-
tive population-based cohort study to investigate the role of
endothelial dysfunction, leukocyte adhesion, and low-grade
inflammatory activity (1) in the development of elevated
UAER (study I) and (2) in linking elevated UAER with the
risk of cardiovascular mortality (study II). We used increased
levels of vWf, sVCAM-1, and CRP as markers of endothelial
dysfunction, leukocyte adhesion, and low-grade inflamma-
tory activity, respectively. For study II, we updated and
extended previously published analyses.16
Methods
The Hoorn Study is a prospective cohort study of disturbances of
glucose tolerance and cardiovascular disease in a general white
population aged 50 to 75 years (n2484). For reasons of efficiency,
we chose to study a smaller (n631), but still randomly selected,
sample in more detail with regard to cardiovascular disease. This
sample was stratified for age, sex, and glucose tolerance status.
Baseline Examination (Studies I and II)
We obtained an early-morning, first-voided, spot urine sample
(n607) to measure the urinary albumin-to-creatinine ratio (ACR).
Of all the urine samples, 32 were excluded because of the use of an
ACE inhibitor. In a representative random sample of 174 subjects, 2
urine collections were available; therefore, the presence of (micro)al-
buminuria for these subjects was based on the mean ACR of the 2
urine collections.
We obtained data on blood pressure, weight, height, and waist and
hip circumference, data on fasting and 2-hour postload glucose,
creatinine, homocysteine, total cholesterol, HDL cholesterol, and
triglyceride levels, and data on vWf, sVCAM-1, and CRP, and we
assessed an ankle-brachial pressure index, a resting ECG, ophthal-
moscopy, and/or fundus photography.7,16–20 Hypertension was de-
fined as diastolic pressure 95 mm Hg, systolic pressure
160 mm Hg, and/or the use of antihypertensive drugs in accor-
dance with guidelines in use at the time the study was designed.
Current smoking was defined as currently smoking cigarettes and/or
cigars. Other definitions are described in Results.
Follow-Up Study I
For the analyses in study I, we focused only on those subjects who,
at baseline, were normoalbuminuric and did not use ACE inhibitors.
All participants were asked to hand in an overnight, first-voided,
untimed spot urine sample. In a representative sample (n161),
subjects were asked to hand in a second set of urine samples within
4 weeks. Of all 340 participants, 4 collected no urine samples, 18
collected 1 sample, 168 collected 2 samples, 10 collected 3 samples,
and 140 collected 4 samples. The urinary ACRs were determined,
and the mean ACR was calculated. Subjects were classified as
having normoalbuminuria when the mean ACR was 2.0 mg/mmol
and as having (micro)albuminuria when the mean ACR was 2.0
mg/mmol.
Follow-Up Study II
Data on the vital status and date of death for each subject were
collected from the mortality register of the municipality of Hoorn or
other local municipalities. For all subjects who had died, the cause of
death was classified according to the ninth edition of the Interna-
tional Classification of Diseases. Cardiovascular mortality was
defined as codes 390 to 459. Information on the cause of death could
not be obtained for 10 (12%) of the deceased subjects, and 1 subject
was lost to follow-up.
Statistical Analyses
Differences between the 2 groups were tested with the Student t test,
the Mann-Whitney test, and the 2 test, as appropriate. To assess
whether determinants were independently associated with the devel-
opment of (micro)albuminuria, logistic regression analyses were
primarily adjusted for all variables that were statistically significant
in the initial analyses, secondarily adjusted for creatinine clearance,
and, finally, adjusted for other variables of interest. To investigate
whether endothelial dysfunction, leukocyte adhesion, or low-grade
inflammation could be the pathogenic link between cardiovascular
mortality and (micro)albuminuria, regression analyses were per-
formed with adjustment for levels of vWf, sVCAM-1, and CRP.
For further information, please see the online supplement, which
can be accessed at http://www.atvb.ahajournals.org.
Results
Study I: Determinants of the Development of
Elevated UAER
The mean duration of follow-up was 6.1 years (standard
deviation 0.7 years, range 4.4 to 7.7 years). The cumulative
incidence of elevated UAER was 14.0% (95% CI 9.7 to 19.3)
among nondiabetic subjects and 22.7% (95% CI 12.9 to 32.5)
among type 2 diabetic patients. The cumulative incidence of
elevated UAER increased with tertiles of sVCAM-1 and CRP
level but not with tertiles of vWf level (Figure 1).
Subjects who died during the follow-up period, compared
with those who participated in the follow-up examination,
were older, more obese, and more often smokers; those who
died, compared with those who survived, also more often had
type 2 diabetes, hypertension, and cardiovascular disease and
higher levels of homocysteine, triglycerides, vWf (1.60 ver-
sus1.29 IU/mL, respectively; P0.01), and CRP (2.30 versus
1.48 mg/mL, respectively; P0.047) at baseline (other data
not shown). The nonresponders (Figure 2) were not materi-
Figure 1. Cumulative incidence of elevated UAER according to
tertiles of vWf, sVCAM-1, and CRP levels (study I). *Estimated
by age–, sex–, and glucose tolerance–adjusted logistic regres-
sion analyses. †Levels of vWf per tertile: first tertile, 0.24 to 0.92
IU/mL; second tertile, 0.93 to 1.39 IU/mL; and third tertile, 1.40
to 3.31 IU/mL. ‡Levels of sVCAM-1 per tertile: first tertile, 548
to 1122 ng/mL; second tertile, 1123 to 1431 ng/mL; and third
tertile, 1432 to 3009 ng/mL. §Levels of CRP per tertile: first ter-
tile, 0.02 to 0.85 mg/L; second tertile, 0.86 to 2.22 mg/L; and
third tertile, 2.23 to 35.18 mg/L.
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ally different from those who did participate in the follow-up
examination regarding the variables shown in Table 1, except
that nonresponders were older (65 versus 63 years, P0.01).
Subjects who developed elevated UAER, compared with
those who did not, were significantly older and more obese; they
had higher systolic blood pressure and higher homocysteine,
sVCAM-1, and CRP levels; and they more often had hyperten-
sion, cardiovascular disease, and retinopathy at baseline (Table
1). Age-adjusted, sex-adjusted, and glucose tolerance status–
adjusted logistic regression analyses showed the development of
elevated UAER to be significantly associated with age, male sex,
systolic blood pressure, presence of hypertension, body mass
index, levels of homocysteine, sVCAM-1, and CRP, and the
presence of cardiovascular disease (Table 1). Analyses per-
formed in nondiabetic and diabetic subjects separately gave
similar results (data not shown). Levels of vWf in the upper
compared with the 2 lower tertiles were not associated with the
development of elevated UAER, either in the entire group (Table
1) or in nondiabetic and diabetic subjects separately (odds ratio
1.06 [95% CI 0.47 to 2.41] and odds ratio 1.19 [95% CI 0.32 to
4.46], respectively).
In multiple regression analyses, the risk of developing ele-
vated UAER associated with high levels of sVCAM-1 and CRP
was independent of other determinants (Table 2). Additional
adjustment for homocysteine level did not materially change the
results (data not shown). Substituting systolic blood pressure or
diastolic blood pressure for hypertension did not materially
change the results either (data not shown). Analyses in nondia-
betic and diabetic subjects, separately, showed somewhat higher,
but not significantly different, odds ratios of developing elevated
UAER associated with sVCAM-1 and CRP levels among
nondiabetic than among diabetic subjects (probability values for
interaction 0.10 and 0.12, respectively; data not shown).
The correlation between vWf and logarithmically transformed
sVCAM-1 was 0.25 (P0.0005); between vWf and logarithmi-
cally transformed CRP, it was 0.10 (P0.10); and between
logarithmically transformed sVCAM-1 and logarithmically
transformed CRP, it was 0.11 (P0.06). The risk of developing
elevated UAER associated with sVCAM-1 levels was not
materially changed after adjustment for vWf or CRP levels
(Table 2, models 5 and 7). Similarly, the risk of developing
elevated UAER for CRP levels was not materially changed after
adjustment for vWf or sVCAM-1 levels (Table 2, models 5 and
6).
Additional Analyses
The following additional analyses did not materially affect
our results: analyses with elevated UAER defined as an ACR
3.0 instead of 2.0 mg/mmol, analyses with elevated
UAER defined as an ACR 2.5 mg/mmol for men and 3.5
mg/mmol for women, analyses with elevated UAER defined
on the basis of the overnight or spot samples only, analyses
with elevated UAER defined on the basis of the median ACR,
analyses after exclusion of subjects who developed “macroal-
buminuria” (as defined by an ACR 30 mg/mmol, n3),
analyses after exclusion of urine samples with a positive
dipstick test for leukocytes and/or nitrite at baseline (n49)
and/or at follow-up (n47), analyses among nondiabetic
subjects that excluded subjects with impaired glucose toler-
ance (n84), analyses after exclusion of subjects with CRP
levels 10.0 mg/L (n10), analyses after exclusion of
subjects with sVCAM-1 levels 1890 ng/mL (upper 10% of
the distribution, n31), and analyses that included blood
groups (a determinant of vWf levels,7 data not shown).
Study II: Can Markers of Endothelial
Dysfunction, Leukocyte Adhesion, and
Inflammatory Activity Explain the Association
Between Elevated UAER and
Cardiovascular Mortality?
After 6.6 years (standard deviation 1.4 year, range 0.5 to 8.2
years) of follow-up, 14% (81, with 35 type 2 diabetic
subjects) of the 574 subjects had died, of whom 37% (30,
with 15 type 2 diabetic subjects) had died of cardiovascular
disease (Figure 2). Subjects who died, compared with those
who survived, more often had elevated UAER (23.5% versus
9.5%, respectively; P0.001) and had higher levels of vWf
(1.57 versus 1.33 IU/mL, respectively; P0.005), sVCAM-1
(1383 versus 1305 ng/mL, respectively; P0.07), and CRP
(2.24 versus 1.62 mg/L, respectively; P0.005).
In the entire group, elevated UAER was associated with an
4-fold increased risk of cardiovascular death after adjusting for
age, sex, and glucose tolerance status (Table 3). Adjustment for
levels of vWf, sVCAM-1, or CRP did not materially change the
results. Analyses in nondiabetic and diabetic subjects separately
showed somewhat higher, but not significantly different, relative
risks of cardiovascular mortality associated with elevated UAER
among diabetic than among nondiabetic subjects (P0.07 for
interaction between type 2 diabetes and elevated UAER, data not
shown); additional adjustment for levels of vWf, sVCAM-1, or
CRP again did not materially change the results.
In previous analyses, we showed age, current smoking, levels
of homocysteine, triglycerides, and HDL cholesterol, and the
presence of hypertension, type 2 diabetes mellitus, retinopathy,
Figure 2. Outline of the 2 studies. *Among subjects who had an
ACR 2.0 mg/mmol, 62 died, of whom 12 were investigated
and included in study I before they died; among subjects who
had an ACR 2.0 mg/mmol, 19 subjects died.
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and cardiovascular disease to be associated with cardiovascular
mortality.16,21 Additional adjustment for these risk factors some-
what decreased the relative risks of cardiovascular mortality for
elevated UAER (eg, relative risk among all subjects 2.97 [1.32
to 6.69]) but did not affect the results of the analyses with vWf,
sVCAM-1, and CRP added (data not shown).
Additional analyses analogous to those performed in study I
(see above) did not materially affect the results (data not shown).
Discussion
We showed that high levels of sVCAM-1 and CRP were
independently associated with the development of elevated
UAER. These data suggest that leukocyte recruitment into the
vessel wall and low-grade inflammation play a pathogenic
role in the development of elevated UAER. We further
showed that the presence of elevated UAER was associated
with a 4-fold increased risk of cardiovascular mortality. This
risk estimate was not materially affected by adjustment for
levels of vWf, sVCAM-1, and CRP, which argues against the
hypothesis that endothelial dysfunction, leukocyte adhesion,
or low-grade inflammation is the pathogenic link between
elevated UAER and the risk of cardiovascular mortality.
High levels of vWf and CRP among subjects who are not
acutely ill are thought to be reasonably specific markers of
endothelial dysfunction and low-grade inflammation, respective-
ly.5,22 In contrast, the interpretation of high sVCAM-1 levels is
less clear.18 High sVCAM-1 levels may reflect increased expres-
sion of membrane-bound VCAM-1 on endothelial and smooth
muscle cells and thus be a marker of generalized vascular
dysfunction.23–25 However, other interpretations cannot be ex-
cluded; one such interpretation is that high sVCAM-1 levels
reflect increased levels of advanced glycation end products,26,27
which can contribute to the development of elevated UAER and
cardiovascular disease by a variety of mechanisms.28
Our findings on CRP support the hypothesis that low-grade
inflammation is causally related to the development of elevated
UAER.15,29 The main stimulators of production of acute-phase
reactants are proinflammatory cytokines. Interleukin-6 may be
an important mediator of mesangial cell proliferation and matrix
overproduction30 but also of an increase in general vascular
permeability without involvement of the kidney. Thus, increased
TABLE 1. Baseline Characteristics According to Albuminuria Status at Follow-Up (Study I)
Persistent Normal UAER
(N266)
Development of Elevated UAER
(N50)
OR (95% CI) per Indicated Difference in Potential
Determinant*
Male/female, n 127/139 30/20 Male vs female 1.49 (1.17–1.88)
Age, y 627 667 Per 5-y increase 1.95 (1.03–3.70)
Impaired glucose tolerance, % 26 32 Vs normal glucose tolerance 1.53 (0.72–3.23)
Type 2 diabetes mellitus, % 19 30 Vs normal glucose tolerance 2.08 (0.96–4.50)
Systolic blood pressure, mm Hg 14520 15823 Per 10 mm Hg increase 1.38 (1.14–1.68)
Hypertension, % 23 56 Yes vs no 3.81 (1.95–7.46)
Waist-to-hip ratio
Men 0.960.06 0.970.07 Per 0.01 increase 1.10 (0.57–1.30)
Women 0.860.08 0.900.07 Per 0.01 increase 1.82 (0.90–3.69)
Body mass index, kg/m2 26.43.4 27.83.7 High vs low¶ 3.11 (1.54–6.28)
Total cholesterol, mmol/L 6.61.1 6.51.4 Per 1-mmol/L increase 0.99 (0.76–1.30)
HDL cholesterol, mmol/L 1.30.4 1.20.3  vs 0.9 mmol/L 1.40 (0.52–3.74)
Triglycerides,† mmol/L 1.5 (0.8–2.8) 1.5 (0.8–2.7) Per 10% increase 0.99 (0.93–1.06)
Homocysteine, mol/L 11.64.3 13.04.0 High vs low# 5.08 (1.12–23.00)
Creatinine clearance,‡ mL/min 8017 7818 Per 1-mL/min increase 1.00 (0.98–1.02)
vW factor, IU/mL 1.260.60 1.290.71 High vs low** 1.09 (0.55–2.17)
sVCAM-1,† ng/mL 1244 (852–1879) 1397 (1035–2047) Per 10% increase 1.14 (1.02–1.27)
CRP,† mg/L 1.29 (0.26–4.88) 2.22 (0.50–9.45) Per 50% increase 1.17 (1.04–1.32)
Cardiovascular disease,§ % 14 34 Yes vs no 2.20 (1.08–4.51)
Retinopathy, % 8 18 Yes vs no 2.33 (0.96–5.67)
Current smokers, % 28 20 Yes vs no 0.73 (0.34–1.59)
OR indicates odds ratio. Values are meanSD unless indicated otherwise.
*OR and 95% CI were obtained by logistic regression analyses with development of elevated UAER as dependent variable, adjusted for age, sex, and
glucose tolerance status, unless it was the variable under consideration.
†Median (10th–90th percentiles).
‡Calculated by the Cockroft-Gault formula.28
§Ankle-brachial pressure index0.90 and/or peripheral bypass operation or amputation and/or Minnesota code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1 on the
ECG, coronary bypass operation or angioplasty, and/or self-reported myocardial infarction.
P0.05.
¶27 vs 27 kg/m2 for men and 26 vs 26 kg/m2 for women.
#19.0 vs 9.1 mol/L.
**Highest vs lower 2 tertiles.
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proinflammatory cytokines, as reflected by increased acute-
phase reactants such as CRP, may cause elevated UAER through
renal and nonrenal vascular mechanisms.
Increased vWf levels were not associated with the develop-
ment of elevated UAER, which is in contrast with some8,9 but
not all29 studies. There are several possible explanations for
these discrepant findings. First, studies that found high vWf
levels to be associated with the development of elevated UAER8
had a shorter duration of follow-up (3.1 to 5.3 years) than did
studies that did not find this association (Yokoyama et al29 and
the present study, 6.6 to 10.0 years). Late-onset elevated UAER
may have a different pathogenesis than does early-onset elevated
UAER.31 Second, 50 of the 509 subjects investigated at baseline
died during follow-up. We have previously shown in this
population that mortality risk is related to having elevated
UAER16 and high vWf levels.7 Indeed, subjects who died had
higher vWf levels at baseline than did those who survived. These
data suggest that compared with subjects who survived, subjects
who died may have been at increased risk of developing elevated
UAER. Therefore, we may have underestimated the association
between increased vWf levels and incident elevated UAER.
The associations between incident elevated UAER and
sVCAM-1 and CRP levels appeared stronger among nondiabetic
than among diabetic subjects. We emphasize that this may just
be the play of chance, although we clearly cannot exclude the
possibility that with regard to the processes reflected by high
sVCAM-1 and CRP levels, the pathogenesis of elevated UAER
differs between nondiabetic and diabetic subjects.32
The present data confirm that elevated UAER is strongly and
independently associated with cardiovascular mortality.1,2 We
investigated 3 possible pathophysiological processes that might
explain this association. We found no clear evidence that this
link was explained by endothelial dysfunction, leukocyte adhe-
sion, or low-grade inflammation. The most important assump-
tion in this conclusion is that these processes are reflected by
levels of vWf, sVCAM-1, and CRP with sufficient accuracy.
This is in fact uncertain, but our finding that all 3 variables are
mutually independently associated with mortality7,18 does argue
in favor of vWf, sVCAM-1, and CRP levels reflecting dissimilar
pathophysiological mechanisms.
What then could explain the link between elevated UAER and
risk of cardiovascular mortality? One possibility is that elevated
UAER reflects a prothrombotic state.33 Alternatively, elevated
UAER may reflect a certain susceptibility to the vascular
adverse effects of a variety of cardiovascular risk factors. This
concept is supported by the observation that determinants of the
development of elevated UAER, such as diabetes, hypertension,
and the processes reflected by high sVCAM-1 and CRP levels,
do not appear to confound the elevated UAER–cardiovascular
disease link (Dinneen and Gerstein,1 Yudkin et al,2 Ridker et
al,22 and the present findings).
In conclusion, we have shown that high levels of sVCAM-1
and CRP are associated with the development of elevated
TABLE 2. ORs of Developing Elevated UAER According to sVCAM-1 and CRP
Level After Adjustment for Potentially Confounding Variables (Study I)
Model Added Variables
OR (95% CI)
sVCAM-1, ng/mL CRP, mg/L
1 Age, sex, impaired glucose
tolerance, and type 2 diabetes
mellitus
1.14 (1.02–1.27) 1.17 (1.04–1.32)
2 Model 1 and hypertension,* body
mass index,† and cardiovascular
disease†
1.14 (1.01–1.29) 1.14 (1.01–1.30)
3 Model 2 and creatinine clearance† 1.14 (1.01–1.29) 1.15 (1.01–1.31)
4 Model 2 and waist-to-hip ratio,
current smoking, and retinopathy
1.16 (1.03–1.31) 1.16 (1.01–1.32)
5 Model 1 and vWf‡ 1.14 (1.02–1.27) 1.17 (1.04–1.32)
6 Model 1 and sVCAM-1§    1.16 (1.03–1.30)
7 Model 1 and CRP‡ 1.12 (1.00–1.25)   
There were 316 subjects (50 cases). A case is a subject who developed elevated UAER. ORs and
95% CIs were according to logistic regression analyses for development of elevated UAER associated
with a 10% increase in sVCAM-1 levels or with a 50% increase in CRP levels.
*Systolic or diastolic blood pressure instead of hypertension gave similar results.
†Described in legend to Table 1.
‡Highest vs the 2 lower tertiles.
§Logarithmically transformed.
TABLE 3. Relative Risk of Cardiovascular Mortality Associated
With the Presence of Elevated UAER After Adjustment for
Levels of vWf, CRP, and sVCAM-1 (Study II)
Model Added Variables Relative Risk (95% CI)
1 Age, sex, impaired glucose tolerance,
and type 2 diabetes mellitus
4.12 (1.94–8.73)
2 Model 1 and levels of vWf* 3.92 (1.85–8.29)
3 Model 1 and levels of sVCAM-1 3.36 (1.55–7.26)
4 Model 1 and levels of CRP* 3.71 (1.74–7.92)
There were 574 subjects; 66 subjects had elevated UAER (ACR2.0
mg/mmol). Relative risk of cardiovascular mortality was associated with
elevated UAER analyzed by Cox multiple regression analyses. Model 1 consists
of stratification variables.
*Highest vs 2 lower tertiles.
Jager et al Albumin Excretion and Cardiovascular Risk 597
UAER. Furthermore, elevated UAER is associated with a 4-fold
increased risk of cardiovascular mortality, which is not materi-
ally affected by adjustment for levels of vWf, sVCAM-1, and
CRP. This may be of clinical relevance, because sVCAM-1 and
CRP levels can be decreased by drug interventions24,34,35 and
because prophylactic administration of aspirin has been found to
reduce the risk of cardiovascular events, particularly among men
with the highest baseline levels of CRP.22
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